First Manhattan
ANIK icon

First Manhattan’s Anika Therapeutics ANIK Stock Holding History

First Manhattan’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-409,852
Closed -$13.8M – 1381
2018
Q4 		$13.8M Hold
409,852
– – 0.09% 130
2018
Q3 		$17.3M Sell
409,852
-82,750
-17% -$3.27M 0.09% 134
2018
Q2 		$15.8M Buy
492,602
+453,902
+1,173% +$18.7M 0.09% 144
2018
Q1 		$1.92M Buy
+38,700
New +$2.19M 0.01% 362

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Manhattan's ANIK Position: Q1 2019 in Review

First Manhattan sold out of Anika Therapeutics (ANIK) in Q1 2019, closing a stake of 409,852 shares — an estimated $13.8M sold.

First Manhattan first reported a position in ANIK in Q1 2018 and held it in 4 quarters. The position peaked at $17.3M in Q3 2018. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

  • First Manhattan reported no remaining Anika Therapeutics position as of Q1 2019 after selling out during the quarter.
  • First Manhattan sold 409,852 Anika Therapeutics shares in Q1 2019, an estimated $13.8M.
  • First Manhattan first reported a position in Anika Therapeutics in Q1 2018 and held it in 4 quarters.
  • First Manhattan's Anika Therapeutics position peaked at $17.3M in Q3 2018.
  • 157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on First Manhattan's 13F filing for Q1 2019, filed 12 Apr 2019.